

# Combined Therapy of Platelet-Rich Plasma and Basic Fibroblast Growth Factor Using Gelatin-Hydrogel Sheet for Rotator Cuff Healing in Rat Models

**Takeshi Kataoka** (✉ [t.kataoka1010@gmail.com](mailto:t.kataoka1010@gmail.com))

Kobe University Graduate School of Medicine <https://orcid.org/0000-0001-7651-9915>

**Yutaka Mifune**

Kobe University Graduate School of Medicine School of Medicine: Kobe Daigaku Daigakuin Igakukei  
Kenkyuka Igakubu

**Atsuyuki Inui**

Kobe University Graduate School of Medicine School of Medicine: Kobe Daigaku Daigakuin Igakukei  
Kenkyuka Igakubu

**Hanako Nishimoto**

Kobe University Graduate School of Medicine School of Medicine: Kobe Daigaku Daigakuin Igakukei  
Kenkyuka Igakubu

**Takashi Kurosawa**

Kobe University Graduate School of Medicine School of Medicine: Kobe Daigaku Daigakuin Igakukei  
Kenkyuka Igakubu

**Kohei Yamaura**

Kobe University Graduate School of Medicine School of Medicine: Kobe Daigaku Daigakuin Igakukei  
Kenkyuka Igakubu

**Shintaro Mukohara**

Kobe University Graduate School of Medicine School of Medicine: Kobe Daigaku Daigakuin Igakukei  
Kenkyuka Igakubu

**Takehiko Matsushita**

Kobe University Graduate School of Medicine School of Medicine: Kobe Daigaku Daigakuin Igakukei  
Kenkyuka Igakubu

**Takahiro Niikura**

Kobe University Graduate School of Medicine School of Medicine: Kobe Daigaku Daigakuin Igakukei  
Kenkyuka Igakubu

**Yasuhiko Tabata**

Laboratory of Biomaterials, Institute for Frontier Life and Medical Sciences, Kyoto University

**Ryosuke Kuroda**

## Research Article

**Keywords:** rotator cuff tear, basic fibroblast growth factor (bFGF), platelet-rich plasma (PRP), rotator cuff repair, rat model, infraspinatus tendon

**Posted Date:** August 12th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-775769/v1>

**License:**   This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

1 Combined therapy of platelet-rich plasma and basic fibroblast growth factor using  
2 gelatin-hydrogel sheet for rotator cuff healing in rat models

3

4 Takeshi Kataoka<sup>1)</sup> M.D., Ph.D., Yutaka Mifune<sup>1)</sup> M.D., Ph.D., Atsuyuki Inui<sup>1)</sup> M.D.,  
5 Ph.D., Hanako Nishimoto<sup>1)</sup> M.D., Ph.D., Takashi Kurosawa<sup>1)</sup> M.D., Ph.D., Kohei  
6 Yamaura<sup>1)</sup> M.D., Ph.D., Shintaro Mukohara<sup>1)</sup> M.D., Takehiko Matsushita<sup>1)</sup> M.D., Ph.D.,  
7 Takahiro Niikura<sup>1)</sup> M.D., Ph.D., Yasuhiko Tabata<sup>2)</sup> Ph.D., D.MedSci., D.Pharm., Ryosuke  
8 Kuroda<sup>1)</sup> M.D., Ph.D.

9

10 1) Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine  
11 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

12 2) Laboratory of Biomaterials, Institute for Frontier Life and Medical Sciences, Kyoto  
13 University

14 53 Kawara-cho Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

15

16 Author

17 Takeshi Kataoka, M.D., Ph.D. E-mail: [t.kataoka1010@gmail.com](mailto:t.kataoka1010@gmail.com)

18

19 Address correspondence to Takeshi Kataoka M.D., Ph.D.

20 Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine

21 7-5-2, Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan

22 Tel: +81-78-382-5985

23 Fax: +81-78-351-6944

24 e-mail: t.kataoka1010@gmail.com

25 **Abstract**

26 **Introduction:** Excellent outcomes of arthroscopic rotator cuff repair for small and  
27 medium tears have been recently reported. However, re-tears after surgery have been a  
28 common complication after surgical repair of large and massive rotator cuff tears and  
29 often occur in early postoperative phase. It was previously reported that basic fibroblast  
30 growth factor and platelet-rich plasma enhanced rotator cuff tear healing. We  
31 hypothesized that this combined therapy could enhance rotator cuff healing after rotator  
32 cuff repair in a rat model. This study aimed to evaluate the efficacy of combined therapy  
33 of platelet-rich plasma and basic fibroblast growth factor with gelatin-hydrogel sheet.

34 **Methods:** To create a rotator cuff defect, the infraspinatus tendon of Sprague Dawley rat  
35 was resected from the greater tuberosity. The infraspinatus tendons were repaired and  
36 covered with gelatin-hydrogel sheet impregnated with PBS (control group), basic  
37 fibroblast growth factor (bFGF group), platelet-rich plasma (PRP group), or both basic  
38 fibroblast growth factor and platelet-rich plasma (combined group). Histological  
39 examinations were conducted using hematoxylin and eosin, safranin O, and  
40 immunofluorescence staining such as Isolectin B4, type II collagen. For mechanical  
41 analysis, ultimate failure load of the tendon-humeral head complex was evaluated at 6  
42 weeks postoperatively.

43 **Results:** In the hematoxylin and eosin staining, the tendon maturing score of the

44 combined group was higher than that of the control group at postoperative 2 weeks. In  
45 the safranin O staining, stronger proteoglycan staining was observed in the combined  
46 group compared with the other groups at postoperative 2 weeks. Vascular staining with  
47 isolectin B4 in 3 treatment groups was significantly higher than that in the control group.  
48 Type II collagen expression in the combined group was significantly higher than those in  
49 the other groups. The ultimate failure load of the combined group was significantly higher  
50 than that of the control group.

51 **Conclusion:** Combined therapy of basic fibroblast growth factor and platelet-rich plasma  
52 promoted angiogenesis; tendon maturing and fibrocartilage regeneration at the enthesis,  
53 which could be enhance the mechanical strength. It was suggested that basic fibroblast  
54 growth factor and platelet-rich plasma enhance both tendon and bone-tendon junction  
55 healing, and basic fibroblast growth factor and platelet-rich plasma were synergistic.

56

57

58 **Key words :** rotator cuff tear, basic fibroblast growth factor (bFGF), platelet-rich plasma  
59 (PRP), rotator cuff repair, rat model, infraspinatus tendon

60

61 **Introduction:** Rotator cuff tear is common in the elderly population and the outcome of  
62 surgical treatment using arthroscopic rotator cuff repair for small cuff tear is satisfactory.  
63 (1) (2) In contrast, surgical treatment of large and massive cuff tear is still challenging  
64 because of re-tear after surgery. Rotator cuff re-tear is a common complication after  
65 surgery that usually occurs in early postoperative phase. (3) (4) The re-tear ratio is  
66 reportedly 14%~66% and re-tear can lead to loss of shoulder motion and shoulder  
67 function, and recurrence of pain. (4) (5) (6) (7) (8) To prevent re-tear after surgery,  
68 enhancement of biological healing and enforcement of mechanical strength at the repaired  
69 site could be required. Footprint augmentation with fascia lata graft is clinically reported  
70 for large and massive rotator cuff tears. (9) Using fascia lata graft, collagen expression  
71 enhancement was observed at the repaired site. Compared with single-row repair, better  
72 mechanical property in fascia lata grafting is also reported. (10) However, harvesting  
73 fascia lata can cause donor site morbidity such as pain, hematoma formation, and scar  
74 formation. The use of tissue engineering technique is an attractive tool to solve this  
75 problem. There are several growth factors that could enhance the tendon healing process.  
76 (11) Basic fibroblast growth factor (bFGF) expression is reported to be upregulated at  
77 healing site 1 week after supraspinatus repair. (12) (13) It was reported that Platelet-rich  
78 plasma (PRP) also enhanced the healing process after rotator cuff repair in a mouse model.  
79 (14) These investigations were performed by a single administration of growth factors

80 without any carriers. Considering the drug-delivery system, carrier of these growth  
81 factors could be important for better effect of drug. Gelatin is a biodegradable polymer  
82 extensively used for medical purposes and its biosafety and biocompatibility have been  
83 demonstrated through long clinical application and a number of tissue engineering  
84 studies.(15-19) Gelatin-hydrogel combined with growth factor successfully enhanced the  
85 tissue regeneration of fracture, ligament injury, and fibrocartilage. (20) (21) We  
86 speculated that controlled release of bFGF and PRP might enhance the regeneration of  
87 repaired site, as growth factors can affect the surrounding tissue in longer period. In this  
88 study, gelatin-hydrogel sheet (GHS) with/without bFGF and PRP is transplanted to the  
89 rotator cuff repaired site in a rat rotator cuff injury model. We hypothesized that this  
90 combined therapy could enhance rotator cuff healing after rotator cuff repair in a rat  
91 model. This study aimed to evaluate the efficacy of combined therapy of platelet-rich  
92 plasma and basic fibroblast growth factor with gelatin-hydrogel sheet.

93

94 **Materials and Methods**

95 All animal experiments were approved by the committee of our institute.

96 *PRP preparation:* PRP was prepared by double-spin method. (22) Sprague Dawley (SD)

97 rats were anesthetized with isoflurane (Wako, Tokyo, Japan) and intraperitoneal injection

98 of pentobarbital sodium (50 mg/kg; Kyoritsu Seiyaku, Tokyo, Japan). Briefly, rat bloods

99 (10 ml) were collected into tubes containing acid-citrate-dextrose solution and

100 centrifuged for 7 min at 450 g and 4°C. Next, the yellow plasma with buffy coat was

101 centrifuged for 5 min at 1600 g and 4°C. The platelet pellet was collected and the

102 thrombolytic pellet in 1 ml of plasma was used as PRP. The density of platelets in the

103 *PRP:* PRP prepared was increased by a factor of 5 when compared with that of the original

104 blood ( $1.5-2.0 \times 10^8$ /ml plasma). To activate PRP for the release of growth factors, the PRP

105 preparation was mixed with CaCl<sub>2</sub> solution at concentrations of 2 wt.% at a ratio of 7:1

106 by volume and then left for 1 h at 37°C.

107 *bFGF:* An aqueous solution of human recombinant bFGF (Kaken Pharmaceutical Co.,

108 Ltd., Tokyo, Japan) was diluted with physiological saline solution (Otsuka

109 Pharmaceutical Co., Ltd., Tokyo, Japan) to give a solution concentration of 500 µg/ml

110 according to the previous report. (13)

111 *GHS preparation:* Pig skin gelatin with a molecular weight of 100,000 Da and an

112 isoelectric point of 5.0 was supplied by Nitta Gelatin Co., Ltd. (Osaka, Japan). After



113 preparing with 5 wt% aqueous solution of gelatin-hydrogel, the solution was cast into  
114 polystyrene dish as thinly as possible and frozen at -80°C in deep freezer. After the  
115 solution was frozen, freeze drying was performed for 48h. Freeze-drying gelatin-hydrogel  
116 was cut into 2 mm × 2 mm segments. The segments were cross-linked by dehydrothermal  
117 treatment at 140 °C for 48 h in a vacuum oven. (23)

118 A solution of 5 ul of PRP or bFGF was dropped onto a GHS for impregnation. Similarly,  
119 empty gelatin hydrogels without bFGF were prepared by adding PBS to the solution.  
120 Finally, 4 kinds of GHS were created according to experimental groups as PBS (control),  
121 PRP, bFGF, and combined groups (PRP and bFGF).

122 *GHS transplantation:* In this study, 40 SD rats (12-week-old) with a mean weight of  
123 250 g (CLEA Japan, Inc., Tokyo, Japan) were used. All operations were performed under  
124 sterile conditions and anesthesia with isoflurane (Wako), intraperitoneal injection of  
125 pentobarbital sodium (50 mg/kg; Kyoritsu Seiyaku), and subcutaneous injection of  
126 lidocaine (2.5 mg/kg, Xylocaine®; AstraZeneca, London, UK) at the surgical site. The  
127 animals were placed in a lateral position, and a 1 cm incision was made over the lateral  
128 border of the acromion. A small portion of the deltoid muscle was divided to expose the  
129 underlying acromion and the infraspinatus tendon. The infraspinatus tendon was carefully  
130 identified (Figure 1A) and cut off at the insertion to the greater tuberosity (Figure 1B).  
131 The footprint was abraded to remove normal entheses. In the right shoulders, tendons were

132 repaired by a transosseous technique using 4-0 nylon suture, and the repaired site was  
133 covered with GHS (Figure 1C, D). Four kinds of GHS were transplanted in each group  
134 (n=10 each group). The deltoid and skin were closed with 4-0 nylon. After transplantation,  
135 all rats were immediately allowed to move freely within their own cage in laminar flow  
136 rack. Rats were euthanized with overdose of isoflurane and intraperitoneal injection of  
137 pentobarbital sodium at the indicated times.

### 138 *Histological Examination*

139 For the histological examination, 6 rats from each group were sacrificed at 2 weeks after  
140 transplantation. The scapular-humeral complexes were harvested and quickly embedded  
141 in optimal cutting temperature compound (Sakura Finetek USA, Inc., Torrance, CA) and  
142 stored at  $-80^{\circ}\text{C}$  for histochemical and immunohistochemical staining as described below.  
143 Tissue sections were stained with hematoxylin and eosin (H&E) and safranin O for  
144 histological characterization of tissue composition, and the histological findings were  
145 evaluated at 2 points: the tendon proper and tendon insertion using light microscopy.  
146 Watkins et al. reported the tendon maturing scoring system to quantitatively evaluate the  
147 regenerated tendon. (24) Six histological parameters, such as cellularity, fibrocytes,  
148 vascularity, fiber diameter, parallel cells, and parallel fibers, were evaluated to identify  
149 the characteristics of the maturity of cellular and intercellular constituents. In the safranin  
150 O staining, proteoglycan content was calculated as a percentage of the pixels of each

151 tendon–bone interface (positive/total pixels) using Adobe Photoshop CC 2015 software  
152 (Adobe Systems Incorporated, San Jose, USA). In immunofluorescence staining,  
153 isolectin B4 antibody (Vector Laboratories, Burlingame, CA), a rat-specific endothelial  
154 marker, was used to assess the regenerated capillaries and neovascularity. Type II  
155 collagen (Col2) antibody (Cosmo Bio Co., Ltd., Tokyo, Japan) was used to assess  
156 fibrocartilage regeneration. Antibodies were used at a 1:100 dilution, and staining was  
157 performed at room temperature for 1 h. DAPI solution was applied for 5 min for nuclear  
158 staining. After staining, we evaluated the number of positively stained cells in 5 randomly  
159 selected fields.

160 *Mechanical analysis:* For mechanical analysis, ultimate failure load of the tendon-  
161 humeral head complex was evaluated at 6 weeks postoperatively.

162 Six weeks after surgery, 4 rats from each group were euthanized, and shoulders were  
163 biomechanically tested. All soft tissues except the infraspinatus tendon-humeral complex  
164 were carefully removed before the biomechanical tests. The prepared infraspinatus-  
165 humeral complex was mounted in a conventional tensile tester (model AGIS 5kN;  
166 Shimadzu, Kyoto, Japan). The humerus was embedded in an aluminum tube using  
167 polymethylmethacrylate. Testing was performed with the shoulder at 60° of abduction in  
168 a testing machine. The humerus was clamped with its long axis in the horizontal plane.  
169 The proximal end of the infraspinatus tendon was glued between 2 pieces of sandpaper.

170 The sandpaper-tendon complex was clamped vertically. The biomechanical testing  
171 protocol that we used was similar to that described by Galatz et al. (25) and Mikolyzk et  
172 al. (26) Specimens were subjected to a preload of 0.2 N and were preconditioned for 5  
173 cycles to 0.38 mm of displacement (approximately 5% of gage length at a rate of  
174 0.1 mm/s). A stress relaxation test was then performed for 300 s at 0.38 mm of  
175 displacement followed by 300 s of recovery. Specimens were then tested to failure in  
176 tension at a rate of 0.1 mm/s. The ultimate failure load was determined for each specimen.

177 *Statistical analysis:* All data are expressed as mean values  $\pm$  standard deviations. One-  
178 way ANOVA analysis followed by Tukey-Kramer analysis was performed for comparison  
179 of 4 groups.  $P < 0.05$  was considered statistically significant. SPSS (version 23.0; IBM  
180 Corporation, Armonk, NY) were used for data analysis.

181

182 **Results**

183 *Histological analysis:* In H&E staining, tendon maturing scores in control, bFGF, PRP,  
184 and combined groups were  $67\pm0.47$ ,  $8.67\pm0.47$ ,  $8.67\pm1.25$ , and  $11.3\pm1.25$ , respectively  
185 (Figure 2). The score in the combined group was significantly higher than that in the  
186 control group at postoperative 2 weeks ( $p < 0.05$ ). The quantitative analysis with safranin  
187 O staining at the tendon–bone junction showed scores of  $7.2\pm0.69\%$ ,  $9.3\pm1.9\%$ ,  
188  $16.2\pm2.9\%$ , and  $25.7\pm2.2\%$  in control, bFGF, PRP, and combined groups, respectively  
189 (Figure 3). The significantly stronger proteoglycan staining was observed at the repaired  
190 enthesis in the combined group compared with the other groups at postoperative 2 weeks  
191 ( $p < 0.05$ ). The percentages of positive cells in vascular staining with isolectin B4 in  
192 control, bFGF, PRP, and combined groups were  $1.4\pm0.38\%$ ,  $3.4\pm0.41\%$ ,  $3.0\pm0.22\%$ ,  
193 and  $3.7\pm0.43\%$ , respectively (Figure 4). The 3 groups with the growth factors showed  
194 significantly higher vascular expression than in the control group ( $p < 0.05$ ). Finally, Col2  
195 expression in control, bFGF, PRP, and combined groups were  $0.34\pm0.12\%$ ,  $0.95\pm0.53\%$ ,  
196  $4.7\pm2.0\%$ , and  $14.6\pm1.9\%$ , respectively (Figure 5). The combined group showed  
197 significantly higher expression than those in the other groups ( $p < 0.05$ ).

198 *Mechanical analysis:* The ultimate failure load in control, bFGF, PRP, and combined  
199 groups were  $10.5\pm2.8\text{ N}$ ,  $15.0\pm1.4\text{ N}$ ,  $15.5\pm2.6\text{ N}$ , and  $21.0\pm5.5\text{ N}$ , respectively (Figure  
200 6). The combined group showed significantly higher failure load than that of the other

201 groups ( $p < 0.05$ ).

202

203 **Discussion**

204 There were many laboratory experiments that used growth factors for tendon healing.  
205 Local administration of bFGF enhanced tendon–bone interface healing. (12) Tokunaga et  
206 al. reported that the use of bFGF stimulates the proliferation of tenogenic progenitor cells  
207 leading to higher expression of tenogenic markers in a rat model (13)PRP contains various  
208 growth factors such as platelet-derived growth factor-B, transforming growth factor $\beta$ -1,  
209 vascular endothelial growth factor, and epithelial growth factor. (27) After PRP activation,  
210 the platelets in PRP release various growth factors through the degranulation of  $\alpha$ -  
211 granules. Then the growth factors exhibit various biological activities. It was reported that  
212 PRP administration into the articular cartilage defect enhanced cartilage regeneration.  
213 (28) The positive effect of PRP after rotator cuff repair in a rat model has also been  
214 reported. (29) In spite of good results with growth factors in laboratory study, clinical  
215 situation might differ because dose and healing duration is different in animal experiments.  
216 The drug-delivery system of growth factors is considered as a key to improve tissue  
217 regeneration. Once the growth factor in solution form is injected, biological activity is not  
218 always expected because the growth factor activity is unstable due to rapid enzymatic  
219 digestion or deactivation. Intra-articular injection of the growth factor solution can be  
220 easily diluted after shoulder joint surgery. Therefore, drug-delivery system of growth  
221 factors is essential to efficiently improve biological functions. The use of GHS has been

222 successful in the controlled release of various growth factors and PRP. (30) Impregnation  
223 of GHS with growth factors and the subsequent adsorption using electrostatic force allow  
224 for the preservation of biological activity. Therefore, growth factors with preserved  
225 biological activity can be released in a sustained manner until degradation of GHS occurs.  
226 This GHS was degraded for 2 weeks, and sustained release of the encapsulated growth  
227 factors occurred. (14) Kabuto et al. compared intra-articular injection of Bone  
228 Morphogenetic Protein-7 (BMP-7) and GHS impregnated with BMP-7 in a rat rotator  
229 cuff repair model. (31) Slow release of BMP-7 was observed in GHS group up to 3 weeks  
230 after surgery yielding better tissue regeneration. In this study, we used bFGF and PRP as  
231 growth factors for rotator cuff regeneration. Among the various kinds of growth factors,  
232 we chose these 2 factors as these are approved growth factors for clinical use in our  
233 country. Administration of single factor with GHS showed better histological outcome  
234 compared with the control group. Moreover, use of both factors showed the best  
235 histological and mechanical property. In a study of mouse ischemic limb, dual release of  
236 PRP and bFGF impregnated in the biodegradable gelatin-hydrogel granules promoted not  
237 only angiogenesis but also maturation of blood vessels. (22) In this study, combined bFGF  
238 and PRP therapy promoted angiogenesis at the tendon–bone interface, which might lead  
239 to better tendon and fibrocartilage regeneration compared with the control.

240 This study has several limitations. First, this rat model was an acute rotator cuff injury



241 model. The animal models may differ from chronic human rotator cuff injury. Second,  
242 the anatomy between the rat shoulder and that of humans are different, and the short  
243 rotator cuff muscles of rat do not form a rotator cuff that is similar to humans. Third, rats  
244 have greater healing capacity than humans; hence the tendon–bone healing process  
245 progressed faster than that in humans. Finally, the dose of growth factors was determined  
246 according to previous report and we did not optimize its dose as growth factor  
247 composition in PRP might differ from patient to patient.

248

249 **Conclusion**

250 Combined bFGF and PRP therapy promoted angiogenesis, tendon maturing and  
251 fibrocartilage regeneration at the enthesis and the mechanical strength. PRP and bFGF  
252 enhance both tendon and bone-tendon junction healing, and b-FGF and PRP were  
253 synergistic. The combined therapy of PRP and bFGF using GHS could synergistically  
254 work and enhanced rotator cuff healing after rotator cuff repair.

255 Abbreviations

256 PBS: Phosphate buffered saline; PRP: platelet-rich plasma; bFGF: basic fibroblast growth  
257 factor; GHS: gelatin-hydrogel sheet; BMP-7: Bone Morphogenetic Protein-7

258

259 Acknowledgement

260 The authors would like to give our special thanks to Ryusuke Tanaka, Minako Nagata,  
261 Maya Yasuda, and Kyoko Tanaka for their skilled technical assistance.

262

263 Funding

264 Funding information is not applicable.

265 Availability of data and materials

266 Not applicable. All data are presented in the manuscript.

267

268 Authors' contributions

269 Set up research was done by TK. Animal surgery was done by TK, TK, KY and SM. Data  
270 analysis (Histology, Mechanical analysis) was done by TK, YM and AI. Statistical  
271 Analysis was done by TK, HN and TM. Manuscript preparation was done by TK, YM,  
272 AI and TN. Supervisor was done by YT and RK.

273

274 Ethics approval and consent to participate

275 The research protocol was approved by the Institutional Animal Care and Use Committee

276 and carried out according to the Kobe University Animal Experimentation Regulations

277 (Permission number 170701.)

278

279 Consent for publication

280 Not applicable.

281

282 Competing interests

283 The authors declare that they have no competing interests.

284

285 References

286 1. Morse K, Davis AD, Afra R, Kaye EK, Schepsis A, Voloshin I. Arthroscopic versus  
287 mini-open rotator cuff repair: a comprehensive review and meta-analysis. *Am J Sports Med.*  
288 2008;36(9):1824-8.

289 2. Sugaya H, Maeda K, Matsuki K, Moriishi J. Functional and structural outcome  
290 after arthroscopic full-thickness rotator cuff repair: single-row versus dual-row fixation.  
291 *Arthroscopy.* 2005;21(11):1307-16.

292 3. Cho NS, Lee BG, Rhee YG. Arthroscopic rotator cuff repair using a suture bridge  
293 technique: is the repair integrity actually maintained? *Am J Sports Med.* 2011;39(10):2108-  
294 16.

295 4. Kim JR, Cho YS, Ryu KJ, Kim JH. Clinical and radiographic outcomes after  
296 arthroscopic repair of massive rotator cuff tears using a suture bridge technique: assessment  
297 of repair integrity on magnetic resonance imaging. *Am J Sports Med.* 2012;40(4):786-93.

298 5. Koh KH, Kang KC, Lim TK, Shon MS, Yoo JC. Prospective randomized clinical trial  
299 of single- versus double-row suture anchor repair in 2- to 4-cm rotator cuff tears: clinical and  
300 magnetic resonance imaging results. *Arthroscopy.* 2011;27(4):453-62.

301 6. Tashjian RZ, Hollins AM, Kim HM, Teefey SA, Middleton WD, Steger-May K, et al.  
302 Factors affecting healing rates after arthroscopic double-row rotator cuff repair. *Am J Sports*  
303 *Med.* 2010;38(12):2435-42.

304 7. Toussaint B, Schnaser E, Bosley J, Lefebvre Y, Gobezie R. Early structural and  
305 functional outcomes for arthroscopic double-row transosseous-equivalent rotator cuff repair.

306 Am J Sports Med. 2011;39(6):1217-25.  
307 8. Zumstein MA, Jost B, Hempel J, Hodler J, Gerber C. The clinical and structural  
308 long-term results of open repair of massive tears of the rotator cuff. *J Bone Joint Surg Am*.  
309 2008;90(11):2423-31.  
310 9. Kokubu T, Mifune Y, Inui A, Kuroda R. Arthroscopic Rotator Cuff Repair With Graft  
311 Augmentation of Fascia Lata for Large and Massive Tears. *Arthrosc Tech*. 2016;5(6):e1235-  
312 e8.  
313 10. Kataoka T, Kokubu T, Muto T, Mifune Y, Inui A, Sakata R, et al. Rotator cuff tear  
314 healing process with graft augmentation of fascia lata in a rabbit model. *J Orthop Surg Res*.  
315 2018;13(1):200.  
316 11. Wurgler-Hauri CC, Dourte LM, Baradet TC, Williams GR, Soslowky LJ. Temporal  
317 expression of 8 growth factors in tendon-to-bone healing in a rat supraspinatus model. *J*  
318 *Shoulder Elbow Surg*. 2007;16(5 Suppl):S198-203.  
319 12. Ide J, Kikukawa K, Hirose J, Iyama K, Sakamoto H, Fujimoto T, et al. The effect of  
320 a local application of fibroblast growth factor-2 on tendon-to-bone remodeling in rats with  
321 acute injury and repair of the supraspinatus tendon. *J Shoulder Elbow Surg*. 2009;18(3):391-  
322 8.  
323 13. Tokunaga T, Shukunami C, Okamoto N, Taniwaki T, Oka K, Sakamoto H, et al.  
324 FGF-2 Stimulates the Growth of Tenogenic Progenitor Cells to Facilitate the Generation of  
325 Tenomodulin-Positive Tenocytes in a Rat Rotator Cuff Healing Model. *Am J Sports Med*.  
326 2015;43(10):2411-22.  
327 14. Castricini R, Longo UG, De Benedetto M, Panfoli N, Pirani P, Zini R, et al. Platelet-  
328 rich plasma augmentation for arthroscopic rotator cuff repair: a randomized controlled trial.  
329 *Am J Sports Med*. 2011;39(2):258-65.  
330 15. Fujita N, Natsushita T, Ishida K, Sasaki K, Kubo S, Matsumoto T, et al. An analysis  
331 of bone regeneration at a segmental bone defect by controlled release of bone morphogenetic  
332 protein 2 from a biodegradable sponge composed of gelatin and  $\beta$ -tricalcium phosphate. *J*  
333 *Tissue Eng Regen Med*. 2012;6(4):291-8.  
334 16. Ishida K, Kuroda R, Miwa M, Tabata Y, Hokugo A, Kawamoto T, et al. The  
335 regenerative effects of platelet-rich plasma on meniscal cells in vitro and its in vivo  
336 application with biodegradable gelatin hydrogel. *Tissue Eng*. 2007;13(5):1103-12.  
337 17. Fukui T, Ii M, Shoji T, Matsumoto T, Mifune Y, Kawakami Y, et al. Therapeutic effect  
338 of local administration of low-dose simvastatin-conjugated gelatin hydrogel for fracture  
339 healing. *J Bone Miner Res*. 2012;27(5):1118-31.  
340 18. Matsuzaki T, Matsushita T, Tabata Y, Saito T, Matsumoto T, Nagai K, et al. Intra-  
341 articular administration of gelatin hydrogels incorporating rapamycin-micelles reduces the  
342 development of experimental osteoarthritis in a murine model. *Biomaterials*.  
343 2014;35(37):9904-11.  
344 19. Tanaka T, Matsushita T, Nishida K, Takayama K, Nagai K, Araki D, et al.  
345 Attenuation of osteoarthritis progression in mice following intra-articular administration of  
346 simvastatin-conjugated gelatin hydrogel. *J Tissue Eng Regen Med*. 2019;13(3):423-32.  
347 20. Oka S, Matsumoto T, Kubo S, Matsushita T, Sasaki H, Nishizawa Y, et al. Local  
348 administration of low-dose simvastatin-conjugated gelatin hydrogel for tendon-bone healing  
349 in anterior cruciate ligament reconstruction. *Tissue Eng Part A*. 2013;19(9-10):1233-43.  
350 21. Zhang S, Matsushita T, Kuroda R, Nishida K, Matsuzaki T, Matsumoto T, et al.  
351 Local Administration of Simvastatin Stimulates Healing of an Avascular Meniscus in a  
352 Rabbit Model of a Meniscal Defect. *Am J Sports Med*. 2016;44(7):1735-43.  
353 22. Matsui M, Tabata Y. Enhanced angiogenesis by multiple release of platelet-rich  
354 plasma contents and basic fibroblast growth factor from gelatin hydrogels. *Acta Biomater*.  
355 2012;8(5):1792-801.  
356 23. Nakajima N, Hashimoto S, Sato H, Takahashi K, Nagoya T, Kamimura K, et al.  
357 Efficacy of gelatin hydrogels incorporating triamcinolone acetonide for prevention of fibrosis  
358 in a mouse model. *Regen Ther*. 2019;11:41-6.  
359 24. Watkins JP, Auer JA, Gay S, Morgan SJ. Healing of surgically created defects in the

360 equine superficial digital flexor tendon: collagen-type transformation and tissue morphologic  
361 reorganization. *Am J Vet Res.* 1985;46(10):2091-6.

362 25. Galatz LM, Silva MJ, Rothermich SY, Zaegel MA, Havlioglu N, Thomopoulos S.  
363 Nicotine delays tendon-to-bone healing in a rat shoulder model. *J Bone Joint Surg Am.*  
364 2006;88(9):2027-34.

365 26. Mikolyzk DK, Wei AS, Tonino P, Marra G, Williams DA, Himes RD, et al. Effect of  
366 corticosteroids on the biomechanical strength of rat rotator cuff tendon. *J Bone Joint Surg*  
367 *Am.* 2009;91(5):1172-80.

368 27. Anitua E, Andia I, Ardanza B, Nurden P, AT. N. Autologous platelets as a source of  
369 proteins for healing and tissue regeneration. *Thromb Haemost.* 2004;91(1):4-15.

370 28. Ersen A, Demirhan M, Atalar AC, Kapicioglu M, Baysal G. Platelet-rich plasma for  
371 enhancing surgical rotator cuff repair: evaluation and comparison of two application methods  
372 in a rat model. *Arch Orthop Trauma Surg.* 2014;134(3):405-11.

373 29. Mascarenhas R, Saltzman BM, Fortier LA, Cole BJ. Role of platelet-rich plasma in  
374 articular cartilage injury and disease. *J Knee Surg.* 2015;28(1):3-10.

375 30. Tabata Y. Biomaterial technology for tissue engineering applications. *J R Soc*  
376 *Interface.* 2009;6 Suppl 3:S311-24.

377 31. Kabuto Y, Morihara T, Sukenari T, Kida Y, Oda R, Arai Y, et al. Stimulation of  
378 Rotator Cuff Repair by Sustained Release of Bone Morphogenetic Protein-7 Using a Gelatin  
379 Hydrogel Sheet. *Tissue Eng Part A.* 2015;21(13-14):2025-33.

380

382 **Figure Legends**

383 Figure 1

384 A: Infraspinatus tendon was identified. B: Infraspinatus tendon was cut off at the insertion  
385 to the greater tuberosity. C: Gelatin-hydrogel sheet (GHS). D: Infraspinatus tendon was  
386 repaired by a transosseous technique, and the repaired site was covered with GHS. (E)  
387 Scheme of ISP (infraspinatus tendon) repair with GHS. Yellow square is transplanted  
388 GHS. (H, humeral head)

389

390 Figure 2

391 H&E staining at 2 weeks postoperatively, A: control group, B: bFGF group, C: PRP group,  
392 D: bFGF+PRP combined group). E: Tendon maturing score. The tendon maturing score  
393 of the combined group was higher than the control group.

394

395 Figure 3

396 Safranin O staining at 2 weeks postoperatively, A: control group, B: bFGF group, C: PRP  
397 group, D: bFGF+PRP combined group. E: Proteoglycan content was calculated as a  
398 percentage of the pixels of each tendon–bone interface (positive/total pixels).

399 Significantly stronger proteoglycan staining was observed at the repaired enthesis in  
400 combined group compared with other groups.

401

402 Figure 4

403 Immunofluorescence staining: isolectin B4 at 2 weeks postoperatively (A: control group,  
404 B: bFGF group, C: PRP group, D: bFGF+PRP combined group). E: The number of  
405 positively stained cells in 5 randomly selected fields. Vascular staining with isolectin B4  
406 in treatment groups was significantly higher than that in the control group.

407

408 Figure 5

409 Immunofluorescence staining: type II collagen at 2 weeks postoperatively (A: control  
410 group, B: bFGF group, C: PRP group, D: bFGF+PRP combined group). E: The number  
411 of positively stained cells in 5 randomly selected fields. Type II collagen in the combined  
412 group was significantly higher than that in other groups.


413

414 Figure 6

415 The ultimate failure load of the combined group was significantly higher than that of the  
416 control group at 6 weeks after surgery.




# Figures




**Figure 1**

A: Infraspinatus tendon was identified. B: Infraspinatus tendon was cut off at the insertion to the greater tuberosity. C: Gelatin-hydrogel sheet (GHS). D: Infraspinatus tendon was repaired by a transosseous technique, and the repaired site was covered with GHS. (E) Scheme of ISP (infraspinatus tendon) repair with GHS. Yellow square is transplanted GHS. (H, humeral head)



**Figure 2**


H&E staining at 2 weeks postoperatively, A: control group, B: bFGF group, C: PRP group, D: bFGF+PRP combined group). E: Tendon maturing score. The tendon maturing score of the combined group was higher than the control group.



**Figure 3**


Safranin O staining at 2 weeks postoperatively, A: control group, B: bFGF group, C: PRP group, D: bFGF+PRP combined group. E: Proteoglycan content was calculated as a percentage of the pixels of each tendon–bone interface (positive/total pixels). Significantly stronger proteoglycan staining was observed at the repaired enthesis in combined group compared with other groups.





**Figure 4**

Immunofluorescence staining: isolectin B4 at 2 weeks postoperatively (A: control group, B: bFGF group, C: PRP group, D: bFGF+PRP combined group). E: The number of positively stained cells in randomly selected fields. Vascular staining with isolectin B4 in treatment groups was significantly higher than that in the control group.



**Figure 5**

Immunofluorescence staining: type II collagen at 2 weeks postoperatively (A: control group, B: bFGF group, C: PRP group, D: bFGF+PRP combined group). E: The number of positively stained cells in 5 randomly selected fields. Type II collagen in the combined group was significantly higher than that in other groups.




Figure 6

The ultimate failure load of the combined group was significantly higher than that of the control group at 6 weeks after surgery.